<code id='44AB13ED42'></code><style id='44AB13ED42'></style>
    • <acronym id='44AB13ED42'></acronym>
      <center id='44AB13ED42'><center id='44AB13ED42'><tfoot id='44AB13ED42'></tfoot></center><abbr id='44AB13ED42'><dir id='44AB13ED42'><tfoot id='44AB13ED42'></tfoot><noframes id='44AB13ED42'>

    • <optgroup id='44AB13ED42'><strike id='44AB13ED42'><sup id='44AB13ED42'></sup></strike><code id='44AB13ED42'></code></optgroup>
        1. <b id='44AB13ED42'><label id='44AB13ED42'><select id='44AB13ED42'><dt id='44AB13ED42'><span id='44AB13ED42'></span></dt></select></label></b><u id='44AB13ED42'></u>
          <i id='44AB13ED42'><strike id='44AB13ED42'><tt id='44AB13ED42'><pre id='44AB13ED42'></pre></tt></strike></i>

          Home / comprehensive / fashion

          fashion


          fashion

          author:entertainment    Page View:2257
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In